Supernus Pharmaceuticals, Inc. SUPN

42.66 (0.63) (1.46%) as of 25 Sep
Market cap
$2.5B
P/E
0.0×

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Revenue
215.00 302.24 408.90 392.76 520.40 579.78 667.24 607.52 661.82 718.95
Revenue Growth
45.80% 40.57% 35.29% (3.95%) 32.50% 11.41% 15.09% (8.95%) 8.94% 8.63%
Cost of Revenue
11.99 15.22 15.36 16.66 52.46 75.06 87.22 83.78 77.91 74.56
Gross Profit
203.02 287.02 393.54 376.10 467.94 504.71 580.02 523.74 583.91 644.39
R&D Expenses
42.79 49.58 89.21 69.10 75.96 90.47 74.55 91.59 108.80 106.24
SG&A Expenses
106.01 137.91 154.70 153.25 200.68 304.76 377.22 336.36 321.58 485.56
Operating Income
54.22 99.54 144.44 148.57 173.70 86.03 46.12 (5.27) 81.67 (62.28)
Non-operating Income/Expense
(3.85) 1.08 (4.27) (1.08) (5.05) (12.85) 14.62 8.04 16.20 13.25
Non-operating Interest Expenses
5.09 1.57 18.11 22.71 23.75 23.42 7.07 2.42 0.00 0.00
EBT
50.37 100.62 140.18 147.49 168.65 73.18 60.74 2.77 97.87 (49.03)
Income Tax Provision
(40.85) 43.33 29.18 34.43 41.70 19.75 0.03 1.45 24.01 (10.48)
Income after Tax
91.22 57.28 110.99 113.06 126.95 53.42 60.71 1.32 73.87 (38.55)
Dividends (Preferred)
— 0.00 — — — — (3.56) — — —
Net Income Common
91.22 57.28 110.99 113.06 126.95 53.42 64.27 1.32 73.87 (38.55)
EPS (Basic)
1.84 1.13 2.13 2.16 2.41 1.01 1.13 0.02 1.34 (0.68)
EPS (Diluted)
1.76 1.08 2.05 2.10 2.36 0.98 1.04 0.02 1.32 (0.68)
Shares (Basic, Weighted)
49.47 50.76 51.99 52.41 52.62 53.10 53.67 54.54 55.10 56.45
Shares (Diluted, Weighted)
51.71 53.30 54.10 53.82 53.69 54.36 61.68 55.51 55.96 56.45
Gross Margin
94.43% 94.97% 96.24% 95.76% 89.92% 87.05% 86.93% 86.21% 88.23% 89.63%
EBIT Margin
25.22% 32.93% 35.33% 37.83% 33.38% 14.84% 6.91% (0.87%) 12.34% (8.66%)
EBT margin
23.43% 33.29% 34.28% 37.55% 32.41% 12.62% 9.10% 0.46% 14.79% (6.82%)
Net Profit Margin
42.43% 18.95% 27.14% 28.79% 24.39% 9.21% 9.63% 0.22% 11.16% (5.36%)
Free Cash Flow Margin
21.58% 37.26% 31.34% 36.09% 25.89% 21.57% 17.45% 18.19% 25.87% 6.40%
EBITDA
57.14 107.16 161.69 166.90 205.53 136.54 137.01 80.00 163.90 27.75
EBIT
54.22 99.54 144.44 148.57 173.70 86.03 46.12 (5.27) 81.67 (62.28)
Income from Continuous Operations
91.22 57.28 110.99 113.06 126.95 53.42 60.71 1.32 73.87 (38.55)
Consolidated Net Income/Loss
91.22 57.28 110.99 113.06 126.95 53.42 60.71 1.32 73.87 (38.55)
EPS (Basic, from Continuous Ops)
1.84 1.13 2.13 2.16 2.41 1.01 1.13 0.02 1.34 (0.68)
EPS (Basic, Consolidated)
1.84 1.13 2.13 2.16 2.41 1.01 1.13 0.02 1.34 (0.68)
EPS (Diluted, from Cont. Ops)
1.76 1.07 2.05 2.10 2.36 0.98 0.98 0.02 1.32 (0.68)
Shares (Diluted, Average)
51.71 53.30 54.10 53.82 53.69 54.36 61.68 55.51 55.96 56.45
EPS (Diluted, Consolidated)
1.76 1.07 2.05 2.10 2.36 0.98 0.98 0.02 1.32 (0.68)
EBITDA Margin
26.57% 35.46% 39.54% 42.50% 39.50% 23.55% 20.53% 13.17% 24.77% 3.86%
Operating Cash Flow Margin
31.07% 37.93% 31.54% 36.44% 26.59% 21.93% 17.51% 18.28% 25.98% 6.58%

Fold the line items

In millions of $ except per-share values · columns are period end dates